Ankylosing Spondylitis, Crohn Disease, Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis
Conditions
Keywords
nutrition
Brief summary
The aim of the study is to describe the real-world profile of patients treated with adalimumab FK in gastroenterology, dermatology or rheumatology in order to evaluate in this population the predictive factors of therapeutic response (in particular nutritional status) and generate hypothesis between nutritional status and therapeutic response.
Interventions
None listed
Sponsors
Fresenius Kabi
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients at least 18 years old who agree to participate in the study and do not object to the use of their health data * A disorder treated with anti-TNF therapy * Whose physician made the decision to initiate adalimumab treatment prior to the study
Exclusion criteria
* Patients participating in an interventional therapeutic trial at the time of inclusion * Patients who are unwilling or unable to fulfil follow-up requirements (patients who cannot be reached by phone or complete the self-administered questionnaire or not fluent in French
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical Global Impression (CGI) | 12 months | The CGI provides an overall clinician-determined summary measure that takes into account all available information, including a knowledge of the patient's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the patient's ability to function. |
Countries
France
Outcome results
None listed